Popular terms

Platelet topics
Growth Factor
Fibroblast
Nanoparticle
Autologous
Leukocytes
Circulation
Transforming Growth Factor
Therapeutical
Platelet Derived Growth Factor
Bone Morphogenetic Protein
Endothelial
Recombinant
Stem Cells
Respiratory System
Dispensing System

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Platelet patents



      

This page is updated frequently with new Platelet-related patent applications.




Date/App# patent app List of recent Platelet-related patents
07/21/16
20160208124 
 Conductive ink composition and conductive architecture for wireless antenna patent thumbnailnew patent Conductive ink composition and conductive architecture for wireless antenna
A conductive ink composition for the wireless antenna with adhesion enhancement by carbon flakes that aims to enormously reduce the solid content of conductor and can be used to print antennas. For example, silver content of the ink composition is greatly decreased due to the absence of insulated binder.

07/21/16
20160207976 
 Recombinant platelet collagen receptor glycoprotein vi and its pharmaceutical use patent thumbnailnew patent Recombinant platelet collagen receptor glycoprotein vi and its pharmaceutical use
The invention relates to glycoprotein vi (gpvi), its isolation, purification, and methods for recombinant production. Especially, the invention relates to the use of gpvi, preferably recombinant gpvi, in the treatment of disorders and pathological events correlated directly or indirectly to blood coagulation disorders such as thrombotic and cardiovascular diseases.
Sanofi-aventis Deutschland Gmbh


07/21/16
20160206783 
 Cross-linked platelet material patent thumbnailnew patent Cross-linked platelet material
This document provides methods and materials involved in making and using cross-linked platelet material (e.g., cross-linked lysate material from human platelets such as human platelets obtained from platelet blood collection preparations or platelet apheresis preparations). For example, methods and materials for cross-linking platelet material (e.g., lysate material obtained from human platelets) to form a matrix (e.g.
Mayo Foundation For Medical Education And Research


07/21/16
20160206657 
 Compositions and minimally invasive methods for treating incomplete tissue repair patent thumbnailnew patent Compositions and minimally invasive methods for treating incomplete tissue repair
Methods are described for using compositions containing platelet-rich plasma for the treatment of a variety of tissue lesions. Particularly, delivery of platelet-rich plasma to bone tissue particularly a vertebral body or in combination with a bone graft are disclosed..

07/21/16
20160206551 
 Methods for the repair and rejuvenation of tissues using platelet-rich plasma compositions patent thumbnailnew patent Methods for the repair and rejuvenation of tissues using platelet-rich plasma compositions
This application relates to cosmetic methods for improving skin conditions. The methods generally include the administration of platelet-rich plasma and cultured autologous cells to a subject after a micro-needling procedure has been performed.

07/21/16
20160205923 
 Activated platelet preservation composition,  preserving activated platelet and preserved activated platelet using the same patent thumbnailnew patent Activated platelet preservation composition, preserving activated platelet and preserved activated platelet using the same
The present invention relates to an activated platelet preservation composition, a method for preserving activated platelet and a preserved activated platelet using the same. Here, the inventive feature relates to an activated platelet preservation composition comprising a divalent cation, chloride, vitamin b, a selenium source and a solvent, a kit using the same, a method for preserving an activated platelet, and a preserved activated platelet using the same.

07/14/16
20160200751 
 Thienopiperidine derivative and use thereof patent thumbnailThienopiperidine derivative and use thereof
The present invention also relates to the uses of the described thienopiperidine derivative in preparing drugs for preventing platelet aggregation and for treating or preventing cardiovascular and cerebrovascular diseases.. .

07/14/16
20160199400 
 Pharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same patent thumbnailPharmaceutical formulations comprising high purity cangrelor and methods for preparing and using the same
The present invention relates to high purity cangrelor, pharmaceutical formulations comprising high purity cangrelor as an active ingredient, methods for preparing such compounds and formulations, and methods for using the pharmaceutical formulations in the inhibition of platelet activation and aggregation.. .
The Medicine Company


07/07/16
20160195554 
 Factors patent thumbnailFactors
A method for determining a prognosis for benefit for a cancer patient receiving immunotherapy treatment involving (a) measuring a level of haematocrit and haemoglobin in a sample from the cancer patient, and (b) comparing the level of haematocrit in the sample to a reference level of platelets and comparing the level of haemoglobin in the sample to a reference level of haemoglobin, wherein a lower level of haematocrit and higher level of haemoglobin in the sample correlates with increased benefit to the patient.. .
Oxford Biomedica (uk) Limited


07/07/16
20160194460 
 Graphene-augmented composite materials patent thumbnailGraphene-augmented composite materials
Composite materials are augmented with functionalized graphene having added amine groups, benzoxazine groups, imide groups, or a combination of amine groups and imide groups on a surface of the graphene, epoxide groups formed on at least one edge of the graphene and/or holes formed through the graphene. The functionalized graphene is integrated into a composite material as a supplement to or as a replacement for either the carbon reinforcement material or the resin matrix material to increase strength of the composite materials, and may be in the form of a functionalized graphene nanoplatelet, a flat graphene sheet or film, or a rolled or twisted graphene sheet or film..
The Boeing Company


07/07/16
20160193751 

Graphene-augmented composite materials


Composite materials having carbon reinforcement fibers impregnated with a matrix material are augmented with functionalized graphene nanoplatelets having amine groups formed on a surface of the graphene nanoplatelets and epoxide groups formed on at least one edge of the graphene nanoplatelets as a supplement to or a replacement for resin matrix material to increase strength of the composite materials. Related methods of increasing strength of composite materials include mixing the functionalized graphene nanoplatelets into the matrix material prior to impregnating the carbon reinforcement fibers, depositing the functionalized graphene nanoplatelets onto the matrix material to form an interlayer, and depositing the functionalized graphene nanoplatelets onto a bed of carbon reinforcement fibers with no resin matrix material.
The Boeing Company


07/07/16
20160193208 

Identification of non-small cell lung carcinoma (nsclc) tumors expressing pdgfr-alpha


The invention discloses a previously unidentified subset of mammalian non-small cell lung carcinomas (nsclc) in which platelet-derived growth factor receptor alpha (pdgfrα) is expressed and is driving the disease, and provides methods for identifying a mammalian nsclc tumor that belongs to a subset of nsclc tumors in which pdgfrα is expressed, and for identifying a nsclc tumor that is likely to respond to a pdgfrα-inhibiting therapeutic. The invention also provides methods for inhibiting the progression of a mammalian nsclc tumor in which pdgfrα is expressed, and for determining whether a compound inhibits the progression of a pdgfrα-expressing mammalian nsclc tumor..
Cell Signaling Technology, Inc.


06/30/16
20160187546 

Dynamic appearance-changing optical devices (dacod) printed in a shaped magnetic field including printable fresnel structures


A printed image is disclosed wherein the image may be in the form of an array of magnetically aligned platelets or flakes that may by uniform in shape and size and wherein the flakes are arranged in a particularly manner to form optically illusive images useful as security devices, or useful in beam steering applications. In one embodiment of this invention printed array is disclosed a plurality of concentric rings of magnetically aligned platelets disposed upon a substrate in the form of a fresnel structure, preferably a fresnel reflector.

06/30/16
20160185981 

Flame retardant composition comprising graphene nanoplatelets


The composition has optimal flame retardant properties even when applied in relatively modest quantities.. .

06/30/16
20160184482 

Platelet-derived growth factor compositions and methods for the treatment of tendon and ligament injuries


The invention provides compositions and methods for treatment of tendon and ligament injuries and/or repair of damaged tendons and ligament. The invention provides compositions comprising a biocompatible matrix and platelet-derived growth factor (pdgf)..

06/23/16
20160177265 

Method for producing megakaryocytes, platelets and/or thrombopoietin using mesenchymal cells


Provided is a megakaryocyte and/or platelet production method, enabling to produce a megakaryocyte and/or platelet from mesenchymal cells such as preadipocytes in a relatively short period of time, simply, in a large amount and at lower cost or more efficiently in vitro and a method for producing tpo simply and in a larger amount. A first invention is a method for producing a megakaryocyte and/or platelet, comprising culturing a mesenchymal cell in a mesenchymal cell culturing basic medium containing an iron ion and an iron transporter and collecting megakaryocytes and/or platelets from a culture.

06/23/16
20160176879 

Novel hydroximic acid derivative and medical application thereof


The present invention relates to a kind of new hydroximic acid derivatives, in particular, hydroximic acid derivatives of pyrazolopyrimidine and their medical applications, which have inhibition to histone deacetylase 1 and two kinds of tyrosine kinases (vascular endothelial cell growth factor receptors as well as platelet-derived growth factor receptors) simultaneously, and thus can be used for treatment of diseases related to those three kinds of enzymes. This kind of compounds both exerts a synergistic effect sufficiently to increase biological activity, and avoids problems caused by different properties and metabolisms, therefore is more practical and has good prospects..

06/23/16
20160175330 

Method of treatment using an association of losartan and acetylsalicylic acid, and kit


The present invention relates to a method of treatment comprising administering an association of an antihypertensive agent and antiplatelet agent, wherein the antihypertensive agent is administered daily and the antiplatelet agent is administered every three days. The invention further comprises a kit comprising the association of the antihypertensive agent and the antiplatelet agent, packed so as to facilitate the compliance and the correct administration of the dosage of treatment by the patient..

06/16/16
20160169866 

Biochemical markers of platelet storage


Compositions and methods determines post-transfusion survival of platelets and the suitability of platelet units for transfusion by measuring the levels of one or more markers in a platelet sample. A method determines post-transfusion survival of platelets (pl t) prior to transfusion, the method comprising the steps of: a) measuring the levels of one or more markers in a pl t sample selected from the group consisting of adenine, 13-hode/9-hode, caprylate, laurate, c-glycosyltryptophan, andro steroid monsulfate 2, and unelucidated compounds (uc) 1-4; b) comparing the level of the one or more markers in the plt sample with the level of the one or more markers present in a control sample, wherein a higher or lower level of the one or more markers in the pl t sample is indicative of post-transfusion survival of platelets..
Puget Sound Blood Center


06/16/16
20160168726 

Production of graphene and graphane


The present invention provides a method for the production in an electrochemical cell of one or more of graphene, graphite nanoplatelet structures having a thickness of less than 100 nm, and graphane, wherein the cell comprises: (a) a negative electrode which is graphitic; (b) a positive electrode which may be graphitic or another material; and (c) an electrolyte selected from (i) an ionic liquid; (ii) a deep eutectic solvent; and (iii) a solid ionic conductor, optionally further comprising (iv) one or more ionic species, wherein the amount of (i), (ii) or (iii) and (iv) is greater than 50 wt % based on the total weight of the electrolyte; and wherein the electrolyte includes a mixture of different cations; and wherein the method comprises the step of passing a current through the cell to intercalate ions into the graphitic negative electrode so as to exfoliate the graphitic negative electrode.. .
The University Of Manchester


06/16/16
20160168540 

Composition for maintaining platelet function


Provided is a composition for maintaining a function of platelets, having as an active ingredient a pyridone derivative represented by the following general formula (i), or a salt thereof (in the formula, ring a, r1, r2, r3, and r4 represent the definitions given in the description).. .
Kyoto University


06/16/16
20160167144 

Method for machining a casing of an aircraft turboshaft engine and scraper tool for implementing said method


A scraper tool for deburring an edge of an aircraft turboshaft engine casing is arranged to be mounted in a milling device. The scraper tool includes a body including, on a first end, a connection for the milling device and, on a second end, a deburring module including a turning lathe platelet including at least one cutting edge arranged so as to deburr the casing edge.
Snecma


06/16/16
20160166241 

Implantable sealable member with mesh layer


The provided technologies provide an implant closure device having a mesh layer formed on a flexible substrate, collectively forming a sealable member, that improves a seal formed over an aperture in a body lumen. The mesh facilitates a faster and more secure adherence of the sealable member to the surrounding edges at the puncture site.
Vivasure Medical Limited


06/09/16
20160161511 

Automated platelet function analyzer and its analytical methods


An automated platelet function analyzer includes a sampling vessel, a preparation vessel, an analysis vessel, a sampling needle, a blood sample syringe, an analysis solution syringe, and a blood mixing device. A method for platelet analysis is also disclosed..
Sinnowa Medical Science & Technology Co., Ltd.


06/09/16
20160161508 

Method for diagnosing neuro-degenerative disease


A method for the diagnosis of alzheimer's disease (ad) or parkinson's disease (pd), including measuring the level of expression of one or more ad markers (table 1) or pd markers (table 2) in a sample of platelets isolated from a person suspected of having ad or pd, and determining whether the levels of expression are altered compared to a control.. .
Randox Laboratories, Ltd., Co. Antrim, United Kingdom


06/09/16
20160161467 

Automated platelet function analyzer and its analytical methods


An automated platelet function analyzer includes a sampling vessel, a preparation vessel, an analysis vessel, a sampling needle, an analysis solution syringe, a detergent syringe, and blood mixing devices. The sampling vessel is placed in a sample holder, which vacillates left and right.
Sinnowa Medical Science & Technology Co., Ltd.


06/09/16
20160159792 

Process for preparation of indolizine based derivatives as potential phosphodiestrase 3 (pde3) inhibitors


The present invention provides compounds of general formula 1 useful as potential phosphodiesterase3 (pde3) inhibitory agents and a process for the preparation thereof. The derivatives of formula 1 can be employed as therapeutics in human and veterinary medicine, where they can be used, for example, for the treatment and prophylaxis of the following diseases: heart failure, dilated cardiomyopathy, platelet inhibitors, cancer and obstructive pulmonary diseases..
Council Of Scientific & Industrial Research


06/09/16
20160158286 

Cell preparations for extemporaneous use, useful for healing and rejuvenation in vivo


The present invention relates to new plasma or new platelet-rich plasma preparations, new cell dissociation methods, new cell associations or compositions, a method of preparation thereof, a use thereof, devices for the preparation thereof and preparations containing such a platelet-rich plasma preparation and cell associations or compositions. Specifically, the invention provides plasma or platelet-rich plasma alone or in cell combinasons preparations for use in tissue regeneration and bone regeneration and pain reduction..

06/09/16
20160157478 

Compositions and methods for preserving donated blood


Blood and platelet storage and rejuvenating compositions that include triciribine, triciribine metabolites, triciribine analogs, and mixtures of the same are disclosed. Such compositions can be useful in methods for treating (e.g., storing and rejuvenating) red blood cells and platelets..
Rythrx Therapeutics, Llc


06/02/16
20160151556 

System and collecting platelets and anticipating plasma return


A blood processing system for collecting plasma reduced platelets and anticipating plasma return includes a venous access device, a blood component separation device, a first return line, a recirculation line, and a second return line. The venous access device draws whole blood from a subject and returns blood components to the subject using a first pump.
Haemonetics Corporation


06/02/16
20160151315 

S isomers of alpha-methyl-hydrocinnamic acid for the treatment of blood disorders


The present intervention generally relates to compositions comprising s-isomer of alpha-methyl-hydrocinnamic acid for the treatment and/or prevention of blood disorders and blood deficiencies, as well as methods for treating blood disorders and/or blood deficiency in a subject by administering a composition comprising s-isomer of alpha-methyl-hydrocinnamic acid to the subject to ameliorate at least one symptom associated with the blood disorder. Another aspect relates to administration of an s-isomer of alpha-methyl-hydrocinnamic acid stimulate multi-lineage hematopoietic cell production in a subject, for example, increasing the numbers of circulating neutrophils, erythrocytes and platelets.

05/26/16
20160146787 

Measuring antiplatelet activity


Provided herein are methods and materials for assessing platelet activity and/or the ability of substances (e.g., small molecule compounds and compositions comprising the same) to inhibit or activate platelet activity. For example, this document provides methods and materials that can include (a) applying abnormal flow conditions (e.g., oscillatory shear stress) to a sample of platelets (e.g., a blood sample or platelet-rich plasma sample) to stimulate the platelets, and (b) assessing the activity of the platelets.
Melaleuca, Inc.


05/26/16
20160145573 

Platelet protection solution having a beta-galactosidase inhibitor


The present invention relates to a platelet protection solution (pps) having an amount of one or more β-galactosidase inhibitors with or without an amount of one or more sialidase inhibitors, and optionally one or more glycan-modifying agents; and one or more of pps components that include a salt, a citrate source, a carbon source, or any combination thereof.. .
Velico Medical, Inc.


05/26/16
20160145108 

Method for manufacturing graphene platelets


A method for manufacturing graphene platelets includes the following steps of: providing a plurality of graphite blocks each including a plurality of stacked graphene layers, between every two graphene layers being a bonding formed by a van der waals force; applying a shear airflow produced by an airflow interface formed between a first flow path and a second flow path by a forward airflow and reverse airflow to the graphite block, the shear airflow having an energy sufficient for damaging the van der waals force to disengage a part of the graphene layers; and collecting a plurality of pieces of the graphene platelets, the graphene platelets including one or multiple of the graphene layers. Thus, the shear airflow of the present invention disengages the graphene layers from the graphite block to form the graphene platelets, thereby providing a simple manufacturing process and promoting mass production at a fast speed..
Taiwan Carbon Nanotube Technology Corporation


05/26/16
20160143896 

Chiral 1-(4-methylphenylmethyl)-5-oxo--pyrrolidine-2-carboxamides as inhibitors of collagen induced platelet activation and adhesion


Chiral 1-(4-methylphenylmethyl)-5-oxo-{n-[(3-t-butoxycarbonyl-aminomethyl)]-piperidin-1-yl}-pyrrolidine-2-carboxamides as inhibitors of collagen induced platelet activation and adhesion. The present invention provides chiral (2s)-1-(4-methyl-phenylmethyl)-5-oxo-(3s)-{n-[(3-t-butoxycarbonyl aminomethyl)]-piperidin-1-yl}-pyrrolidine-2-carboxamide, and (2s)-1-(4-methylphenylmethyl)-5-oxo-(3r)-{n-[(3-t-butoxycarbonyl amino methyl)]-piperidin-1-yl}-pyrrolidine-2-carboxamide of formula 6 and 7 respectively.
Council Of Scientific & Industrial Research


05/26/16
20160143269 

Platelet protection solution having beta-galactosidase and sialidase inhibitors


The present invention relates to a platelet protection solution (pps) having an amount of one or more β-galactosidase inhibitors with or without an amount of one or more sialidase inhibitors, and optionally one or more glycan-modifying agents; and one or more of pps components that include a salt, a citrate source, a carbon source, or any combination thereof.. .
The Brigham And Women's Hospital, Inc.


05/19/16
20160139124 

Method to bioengineer designer platelets using gene editing and stem cell methodologies


A method of creating cells expressing specific platelet alloantigens is disclosed. In one embodiment, the method comprises the steps of (a) combining one or more guide rnas targeting within a platelet alloantigen target locus; (b) adding a repair template comprising a mutation in the target locus flanked by a homology arm on each side, wherein the template may additionally include a diagnostic restriction enzyme site at the target locus; (c) ligating the guide sequence of step (b) into a plasmid which also expresses a nuclease and, optionally, a selectable marker or a reporter gene; (d) transfecting pluripotent cells with the plasmid of step (c) in the presence of an hdr repair oligo; (e) cloning and testing the resulting reporter positive clones for expression of the alloantigen target of interest; and (f) culturing the resulting cells to expand their numbers or to create a differentiated cell type of interest..
Bloodcenter Research Foundaton


05/19/16
20160137629 

Compounds for binding to the platelet specific glycoprotein iib/iiia and their use for imaging of thrombi


The present invention relates to novel fluorine containing compounds, methods for their preparation, the intermediates of the synthesis, their use as diagnostic agents, especially for imaging of thrombi. The invention relates to positron emission tomography (pet) agents and associated precursor reagents, and methods for producing such radiolaveled agents for imaging of thrombi in a mammalian body.
Piramal Imaging Sa


05/12/16
20160130227 

Prodrugs of anti-platelet agents


The invention relates to the compounds of formula ii, formula ia, formula iia or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula ii, formula ia, formula iia and methods for treating or preventing atherothrombosis may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection.
Cellix Bio Private Limited


05/12/16
20160129075 

Compositions and methods for treatment of cardiovascular disease


In other embodiments, the present invention provides methods of administering a gut flora targeting antibiotic to a subject prior to a procedure that is associated with a risk of causing thrombosis, heart-attack, and/or platelet hyper-responsiveness.. .

05/05/16
20160122714 

Serum-free medium containing pdgf for ds cells


The problem to be solved by the present invention is to provide a serum-free medium suitable for culturing of ds cells. The present invention relates to a serum-free medium for culturing of ds cells containing platelet-derived growth factor (pdgf), or to a method for culturing of dermal sheath (ds) cells, using serum-free medium comprising pdgf..
Shiseido Company, Ltd.


05/05/16
20160122433 

Anti-pdgfr-beta antibodies and uses thereof


The present invention provides antibodies that bind to platelet derived growth factor receptor beta (pdgfr-beta) and methods of using the same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human pdgfr-beta with high affinity.
Regeneron Pharmaceuticals, Inc.


05/05/16
20160121036 

Extemporaneous preparation of autologous fibrin


An autologous fibrin is prepared extemporaneously from either a full blood sample or a prepared sample of poor platelet plasma wherein the latter is subjected to a dedicated treatment and combined isolation process performed by a removable single-use device wherein blood or plasma components are separated and subsequently treated individually to be eventually combined by the user outside the system. The the system includes a platform and a removable single-use device both being designed to cooperate mechanically..
Avance Medical SÀrl


05/05/16
20160120955 

Compositions comprising collagen and prp for tissue regeneration


A composition of matter is disclosed which comprises crosslinked collagen, platelet rich plasma (prp) and an inorganic salt. Methods of generating same and uses thereof are also disclosed..
Collplant Ltd.


05/05/16
20160120944 

Systemic and local ex vivo gene therapy of the skeleton


Methods are disclosed herein for increasing bone mass and strength or bone fracture healing in a subject. The methods include administering to the subject a therapeutically effective amount of multipotent stem cells, wherein each multipotent stem cell is transformed with a recombinant nucleic acid molecule comprising a heterologous promoter operably linked to a nucleic acid encoding platelet derived growth factor (pdgf) b, and wherein the multipotent stem cells express a sufficient amount of pdgfb to increase bone mass and strength or bone fracture healing.
Loma Linda University


05/05/16
20160120856 

Method for inhibiting platelet aggregation


A method for inhibiting platelet aggregation in a patient in need thereof, comprising 1) administering to the patient a bolus injection of an active drug, in an amount of between about 25 μg/kg, and 2) administering to the patient, after the bolus injection, an intravenous infusion for a period of between about 12 hours and about 72 hours, of the active drug, in an amount of about 0.15 μg/kg/min, wherein the active drug is tirofiban or a salt thereof.. .
Medicure International Inc.


04/28/16
20160115601 

Electrochemical process for production of graphene


A process of producing graphene and/or graphite nanoplatelet structures by the electrochemical reduction of carbon oxide in an electrochemical cell is provided, wherein the cell includes (a) a negative electrode including a transition metal, transition metal-containing alloy, transition metal-containing oxide, transition metal containing ceramic, or a combination thereof; (b) a positive electrode; and (c) an electrolyte; wherein the process includes the step of passing a current between the electrodes in the presence of the carbon oxide.. .
The University Of Manchester


04/28/16
20160115324 

Coating compositions and coating products made therefrom


A coating composition and coating products made therefrom, containing modified inorganic nanoplatelets that form mesomorphic structure in a resin phase. The coating products exhibit low permeation/penetration properties, and can be used as anti-corrosion or barrier coatings..
Texas A&m University


04/28/16
20160114095 

Methods and systems for collecting mononuclear cells


A method for obtaining mncs is set forth. The method includes: separating mononuclear cells from a biological fluid that includes red blood cells, plasma and platelets and collecting a targeted number of mononuclear cells in a suspension including plasma and residual red blood cells and platelets; concentrating the separated mononuclear cells; removing plasma from the concentrated mononuclear cells until the amount of residual plasma remaining with the concentrated mononuclear cells reaches a pre-determined volume; and adding a crystalloid solution to the concentrated mononuclear cells.
Fenwal, Inc.


04/28/16
20160114010 

Methods for treating bleeding disorders using a platelet subpopulation


The present invention relates to a platelet subpopulation with high binding capacity to recombinant activated factor vii (rfviia), and its use for the treatment of bleeding disorders and for determining whether a subject is a candidate for treatment with rfviia.. .
Baxalta Gmbh


04/21/16
20160106908 

System and the re-anticoagulation of platelet rich plasma


A method for the re-anticoagulation of platelet rich plasma in a blood apheresis system includes priming the blood apheresis system with anticoagulant, such that a volume of anticoagulant is transferred to a prp container. The method may then transfer the anticoagulant within the prp container to a red blood cell container, and collect a volume of platelet rich plasma within the prp container.

04/21/16
20160106780 

Methods and compositions for optimized expansion and implantation of mesenchymal stem cells


Compositions and methods are provided for the optimized expansion and implantation of mesenchymal stem cells into a patient in need thereof. Autologous mesenchymal stem cells (mscs) to a patient in need of mscs are harvested, expanded within novel growth parameters under the influence of autologous growth factors located on the patient's platelets..

04/21/16
20160106779 

Neutrophil-depleted whole blood and platelet rich plasma compositions


A particle/cell separation device is described which is particularly adapted for neutrophil depletion from a preparation of whole blood or platelet-rich plasma. Also described are blood and platelet rich plasma compositions produced using the device which are neutrophil-depleted..

04/14/16
20160104472 

Acoustic and vibrational energy absorption metamaterials


A substantially acoustically transparent planar, rigid frame divided into a plurality of individual, substantially two-dimensional cells is used to construct a sound absorption panel. A sheet of a flexible material is fixed to the rigid frame, and a plurality of platelets fixed to the sheet of flexible material such that each cell is provided with a respective platelet, thereby establishing a resonant frequency, establishing an increase in an absorption coefficient of the panel.

04/14/16
20160103142 

Blood-platelet test method and blood-platelet test device


A method for testing platelet function, wherein platelet function is tested by allowing anticoagulated blood, to which a weak platelet-activating reagent has been mixed, to pass through a capillary having a platelet-adhesive surface on at least a part of its inner surface, and observing or measuring the behavior of the blood in the capillary.. .

04/14/16
20160101604 

Composite flame barrier laminate for a thermal and acoustic insulation blanket


A multilayer laminate comprising a first polymeric film layer capable of withstanding a temperature of at least 200 c for at least 10 min, a first adhesive layer having an areal weight of from 2 to 40 gsm capable of activation at a temperature of from 75 to 200 degrees c., an inorganic refractory layer comprising platelets in an amount of at least 85% by weight with a dry areal weight of 15 to 50 gsm and having a residual moisture content of no greater than 10 percent by weight, a second adhesive layer having an areal weight of from 4 to 40 gsm capable of activation at a temperature of from 75 to 200 degrees c. And a second polymeric film layer capable of withstanding a temperature of at least 200 c for at least 10 minutes..

04/14/16
20160101130 

Silver nanoplate compositions and methods


Embodiments of the present invention relate to methods for preparing high optical density solutions of nanoplates, such as silver nanoplates or silver platelet nanoparticles, and to nanoparticles, solutions and substrates prepared by said methods. The process can include the addition of stabilizing agents (e.g., chemical or biological agents bound or otherwise linked to the nanoparticle surface) that stabilize the nanoparticle before, during, and/or after concentration, thereby allowing for the production of a stable, high optical density solution of silver nanoplates.

04/14/16
20160100912 

Methods, inserts, and systems useful for endodontic treatment


Devices, methods, inserts, and systems useful in endodontic treatments, involving, for example, a shaped regenerative endodontic insert that contains platelet-fibrin matrix; certain shaped insert embodiments are formed by molding in a cavity mold, optionally as part of a mold assembly.. .

04/07/16
20160096735 

Method for preparation and separation of atomic layer thickness platelets from graphite or other layered materials


A method and system of separating graphene nanoplatelets (gnps) from initial graphite raw material is disclosed. The raw material is exfoliated to create a percentage of separated gnps in a resulting bulk mixture.
Graphene Laboratories Inc.


04/07/16
20160095958 

Bone regeneration using stromal vascular fraction, platelet-derived growth factor-rich hydrogel, three-dimensional printed poly-epsilon-caprolactone scaffolds


The presently disclosed subject matter focuses on recapitulating the heterotypic interactions needed to maximize the co-development of vasculature and bone. More particularly, the presently disclosed subject matter explores the potential of cellular aggregation and temporal presentation of factors to induce the cell-cell signaling events required to stimulate ascs to self-organize into vascularized bone.
The Johns Hopkins University


04/07/16
20160095834 

Food and drink


The present invention provides a food or drink that emits no offensive odor typified by a fish odor in any form of the food or drink, such as liquid, gel, semi-solid, or solid form, and also suppresses emission of an offensive odor due to time-dependent changes. Further, a food or drink is provided that has, particularly, a superior action of inhibiting platelet aggregation to that of conventional fish-derived epa and dha-containing food.
Nikken Kagaku Co., Ltd.


03/31/16
20160089387 

Treating and preventing disease with tma and tmao lowering agents


Provided herein are compositions, systems, and methods for treating a disease, such as kidney and/or cardiovascular disease, with an agent that reduces the production of trimethylamine (tma) or trimethylamine-n-oxide (tmao) in a subject. In certain embodiments, the agent is: i) 3,3-dimethyl-1-butanol (dmb) or a dmb derivative or related compound, ii) acetylsalicylic acid or derivative thereof (e.g., with an enteric coating for delivery to the colon and/or cecum); iii) a flavin monooxygenase 3 (fmo3) inhibitor; iv) a gut tma lyase inhibitor; v) an antibiotic or antimicrobial; vi) a probiotic or prebiotic; vii) an antiplatelet agent; or viii) a tma and/or tmao sequestering agent..
The Cleveland Clinic Foundation


03/31/16
20160089386 

Treating and preventing disease with tma and tmao lowering agents


Provided herein are compositions, systems, and methods for treating a disease, such as kidney disease, with an agent that reduces the production of trimethylamine (tma) or trimethylamine-n-oxide (tmao) in a subject. In certain embodiments, the agent is: i) 3,3-dimethyl-1-butanol (dmb) or a dmb derivative or related compound, ii) acetylsalicylic acid or derivative thereof (e.g., with an enteric coating for delivery to the colon and/or cecum); iii) a flavin monooxygenase 3 (fmo3) inhibitor; iv) a gut tma lyase inhibitor; v) an antibiotic or antimicrobial; vi) a probiotic or prebiotic; vii) an antiplatelet agent; or viii) a tma and/or tmao sequestering agent..
The Cleveland Clinic Foundation


03/24/16
20160083962 

Colored roofing granules with increased solar heat reflectance, solar heat-reflective shingles and process for producing same


Solar-reflective roofing granules having deep-tone colors are formed by coating base mineral particles with a coating composition including an infrared-reflective pigment. Color is provided by a colored infrared pigment, a light-interference platelet pigment, or a metal oxide..
Certainteed Corporation


03/24/16
20160083264 

Preparation of suspensions


A method for preparing a suspension of ldh particles comprising the steps of: preparing ldh precipitates by coprecipitation to form a mixture of ldh precipitates and solution; separating the ldh precipitates from the solution; washing the ldh precipitates to remove residual ions; mixing the ldh precipitates with water; and subjecting the mixture of ldh particles and water to a hydrothermal treatment step by heating to a temperature of from greater than 80° c. To 150° c.
The University Of Queensland


03/24/16
20160082047 

Compositions containing platelet contents


This document provides methods and materials relating to platelet lysates. For example, methods and materials for using platelet lysate compositions to grow adult stem cells, to differentiate adult stem cells, to grow primary cell cultures, to grow tumor stem cells, and to identify effective growth factors are provided..
Mayo Foundation For Medical Education And Research


03/24/16
20160081932 

Neutrally-charged synthetic platelets to mitigate complement response


The invention provides for compositions comprising nanoparticles comprising a core, water-soluble polymer and an rgd peptide and a poloxamer.. .
Case Western Reserve University


03/17/16
20160079319 

Dual-mode pixels including emissive and reflective devices, and dual-mode display using the pixels


A dual-mode display including a substrate and a plurality of sub-pixels on the substrate, in which each sub-pixel includes, a reflective device having an optical filter function which reflects different color according to electrical signals applied from outside the display, and an emissive device disposed on the reflective device, wherein the emissive device includes a cathode and an anode, and the cathode and the anode include a carbon-based material including graphene sheets, graphene flakes, and graphene platelets, and a binary or ternary transparent conductive oxide including indium oxide, tin oxide, and zinc oxide.. .
Electronics And Telecommunications Research Institute


03/17/16
20160077089 

Platelet allo-antigen typing and platelet antibody tests


The present invention relates to methods for the detection of human platelet alloantigens (hpas) on human platelets, methods for the detection of human antibodies against hpas, and diagnostic test devices for carrying our said methods.. .
Davos Diagnostics Ag


03/17/16
20160076077 

Method for thrombogenicity testing of implanted medical device


A method of determining the thrombogenicity of an implantable medical device is disclosed. The implanted device is exposed in vitro to platelet rich plasma, the activity of an indicator is assayed, and the thrombogenicity is determined..
Abbott Cardiovascular Systems Inc.


03/17/16
20160075851 

Silver nanoplate compositions and methods


Embodiments of the present invention relate to methods for preparing high optical density solutions of nanoparticle, such as nanoplates, silver nanoplates or silver platelet nanoparticles, and to the solutions and substrates prepared by the methods. The process can include the addition of stabilizing agents (e.g., chemical or biological agents bound or otherwise linked to the nanoparticle surface) that stabilize the nanoparticle before, during, and/or after concentration, thereby allowing for the production of a stable, high optical density solution of silver nanoplates.
Sienna Labs, Inc.


03/17/16
20160075790 

Antibody polypeptides that antagonize cd40l


Antibody polypeptides that specifically bind human cd40l are provided. The antibody polypeptides do not activate platelets.
Bristol-myers Squibb Company


03/17/16
20160075660 

Pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto


Pyrazole derivatives of formula (ia) and pharmaceutical compositions thereof that modulate the activity of the serotonin 5ht2a receptor. Formula (ia).
Arena Pharmaceuticals, Inc.


03/17/16
20160075164 

Security element comprising a volume hologram


The present invention relates to a security element (20) to be built into an item, particularly a document (10), said security element comprising a holographic layer, enabling a volume hologram to be generated, and a non-holographic variable opacity structure generated by the presence of: a) one or more cutout(s) and/or at least partially translucent areas and moreover at least partially opaque area(s); and/or b) oriented platelet pigments. The variable opacity structure is at least partially placed over the hologram within a region of the security element observable in transmitted light..
Arjowiggins Security


03/17/16
20160074482 

Compositions and methods for producing vascular occlusion using a solid-phase platelet binding agent


The present invention relates generally to methods and compositions for targeting and delivering solid-phase platelet-dependent vascular occlusion agents. In particular, particles or coils or stents coated with platelet binding agents are directed to target vasculature, such as the vasculature of solid tumor masses or av-malformations or aneurysms or endoleaks; the solid-phase agent then binds and activates platelets, which in turn bind and activate other platelets.
Imbiotechnologies Ltd.


03/17/16
20160074481 

Clottable concentrate of platelet growth factors and preparation method thereof


The present disclosure relates to a clottable concentrate of platelet growth factors for therapeutic and/or cosmetic use, preferably comprising the growth factors pdgf, tgt-β, igf, egf, ctgf, bfgf and vegf. In a preferred embodiment, the clottable concentrate of platelet growth factors does not induce blood cell-related transfusion reactions.
Zheng Yang Biomedical Technology Co., Ltd.


03/17/16
20160074479 

Methods of treating spinal disorders using autologous protein solutions


Methods for treating a spinal disorder, such as spinal pain or spinal inflammation, using a blood-derived composition having two or more of il1-ra, stnf-r1, stnf-rii, igf-i, egf, hgf, pdgf-ab, pdgf-bb, vegf, tgf-β1, and sil-1rii. Compositions may also contain white blood cells and platelets..

03/10/16
20160069914 

The detection of restenosis risk in patients receiving a stent


Provided is a method of selecting a stent for implantation in the circulatory system of a human being. The method comprises obtaining a blood sample from a patient who requires implantation of a stent and testing said blood sample to determine a platelet coagulability level.

03/10/16
20160067313 

Assessment of cardiac health and thrombotic risk in a patient


The invention features methods and compositions for assessing risk, particularly immediate risk, of thrombotic events in patients with suspected or known vascular disease, and more particularly to assessing risk of thrombotic events in patients with coronary artery disease, particularly acute myocardial infarction, stroke, unstable angina, stable angina, or restenosis. Risk of thrombosis can be assessed by analysis of platelet reactivity and/or velocity of thrombin or fibrin formation, and determining whether the patient has a score associated above a risk threshold value.

03/10/16
20160067301 

Antagonism of abcg4, lyn kinase, and c-cbl e3 ligase to increase platelet count as therapy for thrombocytopenia


The present invention provides a method of treating a subject to increase the subject's platelet count which comprises administering to the subject an amount of one or more of an antagonist or inhibitor of abcg4, lyn kinase or c-cbl effective to antagonize or inhibit such abcg4, lyn kinase or c-cbl so as to thereby increase the subject's platelet count.. .
The Trustees Of Columbia University In The City Of New York


03/10/16
20160067216 

Composition of a 5-ht2a serotonin receptor modulator useful for the treatment of disorders related thereto


The present invention relates to certain compositions of a 5-ht2a serotonin receptor modulator and methods for their preparation. The compositions disclosed herein are useful for increasing slow wave sleep, improvise sleep consolidation, improving sleep maintenance and improving sleep quality, and for treating insomnia and related sleep disorders, dyssomnias, parasomnias and nonrestorative sleep and the like.
Arena Pharmaceuticals


03/10/16
20160067200 

Uses of 6-aminohexanoic acid to manage bleeding conditions


This disclosure relates to the use of eaca (6-aminohexanoic acid) as an antifibrinolytic for the prevention of thrombocytopenic bleeds. In certain embodiment, the disclosure relates to methods of preventing bleeding in patients with thrombocytopenia resulting from hematological malignancies by administering 6-aminohexanoic acid, salts, or prodrugs thereof prophylactically to a subject in need thereof.
Emory University


03/03/16
20160062258 

Electrophotographic printing


The present disclosure relates to a liquid electrophotographic ink composition comprising clay platelets. Also disclosed herein is a method for electrophotographic printing, and a print substrate..
Hewlett-packard Indigo B.v.


03/03/16
20160061814 

Microfluidic devices for measuring platelet coagulation and associated systems and methods


The present technology relates generally to microfluidic devices for measuring platelet coagulation, and associated systems and methods. In some embodiments, a fluidics device includes an array of microstructures including pairs of generally rigid blocks and generally flexible posts.
University Of Washington


03/03/16
20160058054 

Aqueous extract of tomato-processing waste having platelet anti-ag and antithrombotic activities and the production thereof


A method of producing an aqueous extract from tomato agroindustrial waste (tomasa) includes i) milling or grinding solids resulting from the tomato agroindustrial waste (tomasa); ii) solubilizing the solids of i) with a solvent; iii) extracting selected compounds from ii) the solution by ultrasound; and iv) filtering the suspension to separate solids from tomasa aqueous extract; and obtaining tomasa aqueous extract.. .
Centro De Estudios En Alimentos Procesados (ceap)


03/03/16
20160057994 

Aplatelet clays for sustained release of active ingredients


A method of forming an active control ingredient that controls target living species over an extended period of time commences by providing a clay material that has a structure substantially depleted of platelets (“aplatelet”). The aplatelet clay material is heated with a solid active control agent to a temperature of at least about 10° c.
Bioguard Research And Development, Inc.


02/25/16
20160056216 

Dual-mode pixels including emissive and reflective devices, and dual-mode display using the pixels


A dual-mode display including a substrate and a multiple sub-pixels on the substrate, in which each sub-pixel includes, a color selection reflector, and an optical shutter disposed on the color selection reflector, and an emissive devised disposed on the shutter, wherein the emissive device includes a cathode and an anode, and the cathode and the anode include a carbon-based material including graphene sheets, graphene flakes, and graphene platelets, and a binary or ternary transparent conductive oxide including indium oxide, tin oxide, and zinc oxide.. .
Electronics And Telecommunications Research Institute


02/25/16
20160054326 

Rare cell concentration


A ratio of rare cells to non-rare cells in a blood sample suspected of containing rare cells and non-rare cells is enhanced. A treated blood sample is prepared by providing in combination the blood sample, a platelet deactivation agent, a fibrin-formation-arresting agent and fibrin in an amount sufficient to cause a predetermined level of agglutination of the rare cells.
Siemens Healthcare Diagnostics Inc.


02/25/16
20160053266 

Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics


Materials and methods are provided for producing and using aptamers useful as oncology therapeutics capable of binding to pdgf, pdgf isoforms, pdgf receptor, vegf, and vegf receptor or any combination thereof with great affinity and specificity. The compositions of the present invention are particularly useful in solid tumor therapy and can be used alone or in combination with known cytotoxic agents for the treatment of solid tumors.
Archemix Llc




Platelet topics: Growth Factor, Fibroblast, Nanoparticle, Autologous, Leukocytes, Circulation, Transforming Growth Factor, Therapeutical, Platelet Derived Growth Factor, Bone Morphogenetic Protein, Endothelial, Recombinant, Stem Cells, Respiratory System, Dispensing System

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Platelet for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Platelet with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.5088

4656

1 - 1 - 102